Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT03657355
- Locations
- 🇨🇦
Altasciences Company Inc., Montreal, Canada
🇺🇸Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park, Kansas, United States
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 144
- Registration Number
- NCT03642028
- Locations
- 🇺🇸
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States
🇺🇸San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Theodore R. Brown, MD MPH
- Target Recruit Count
- 34
- Registration Number
- NCT03110315
- Locations
- 🇺🇸
EvergreenHealth Multiple Sclerosis Center, Kirkland, Washington, United States
Sleep Quality and Amyloid-Beta Kinetics
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT03077620
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03034018
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Howard University
- Target Recruit Count
- 27
- Registration Number
- NCT02849548
- Locations
- 🇺🇸
Clinical Research Unit; Howard University Hospital, Washington, District of Columbia, United States
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Jichi Medical University
- Target Recruit Count
- 82
- Registration Number
- NCT02849184
- Locations
- 🇯🇵
Yamasaki family clinic, Hyogo, Japan
🇯🇵Takahira Internal Medicine Clinic, Fukuoka, Japan
🇯🇵Yagi hospital, Tokyo, Japan
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2019-12-11
- Target Recruit Count
- 20
- Registration Number
- NCT02785406
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
- Conditions
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 285
- Registration Number
- NCT02750306
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Burdick, Daniel, M.D.
- Target Recruit Count
- 21
- Registration Number
- NCT02729714
- Locations
- 🇺🇸
Evergreenhealth Booth Gardner Parkinsons Care Center, Kirkland, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.